Stifel Financial Corp Grows Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Stifel Financial Corp increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 99.3% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 37,207 shares of the biotechnology company's stock after purchasing an additional 18,537 shares during the period. Stifel Financial Corp's holdings in Sarepta Therapeutics were worth $4,647,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. Innealta Capital LLC bought a new stake in Sarepta Therapeutics during the 2nd quarter worth approximately $31,000. Huntington National Bank increased its holdings in Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 175 shares in the last quarter. Nkcfo LLC bought a new position in Sarepta Therapeutics during the 2nd quarter worth about $43,000. Riggs Asset Managment Co. Inc. increased its holdings in Sarepta Therapeutics by 33.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 75 shares in the last quarter. Finally, UMB Bank n.a. grew its holdings in shares of Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 197 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock traded up $3.08 during trading hours on Monday, hitting $126.79. 741,418 shares of the company were exchanged, compared to its average volume of 1,221,801. The firm has a fifty day simple moving average of $123.30 and a 200 day simple moving average of $131.55. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 52-week low of $89.92 and a 52-week high of $173.25. The stock has a market capitalization of $12.11 billion, a price-to-earnings ratio of 101.43 and a beta of 0.77.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Piper Sandler cut their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. HC Wainwright lowered their target price on shares of Sarepta Therapeutics from $80.00 to $75.00 and set a "sell" rating on the stock in a report on Tuesday, December 3rd. Guggenheim lifted their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. William Blair raised shares of Sarepta Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. Finally, Evercore ISI decreased their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $178.71.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the firm's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares of the company's stock, valued at $738,234. This trade represents a 21.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.70% of the stock is currently owned by company insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.